Biomolecule-based engineered nanoparticles for Cancer Theranostics

Coordination Chemistry Reviews, Journal Year: 2025, Volume and Issue: 530, P. 216489 - 216489

Published: Feb. 3, 2025

Language: Английский

---

RNA nanotherapeutics for hepatocellular carcinoma treatment

Theranostics, Journal Year: 2024, Volume and Issue: 15(3), P. 965 - 992

Published: Dec. 2, 2024

Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related mortality worldwide, particularly due to the limited effectiveness current therapeutic options for advanced-stage disease. The efficacy traditional treatments is often compromised by intricate liver microenvironment and inherent heterogeneity. RNA-based therapeutics offer promising alternative, utilizing innovative approach targeting aberrant molecular pathways modulating tumor microenvironment. integration nanotechnology in this field, through development advanced nanocarrier delivery systems, especially lipid nanoparticles (LNPs), polymer (PNPs), bioinspired vectors, enhances precision RNA therapies. This review highlights significant progress nanotherapeutics HCC treatment, covering micro (miRNA), small interfering (siRNA), message (mRNA), activating (saRNA) mediated gene silencing, protein restoration, activation, cancer vaccines, concurrent therapy. It further comprehensively discusses prevailing challenges within landscape provides forward-looking perspective on potential transform treatment.

Language: Английский

---

PAMAM/miR-144 Nanocarrier System Inhibits the Migration of Gastric Cancer by Targeting mTOR Signal Transduction Pathway

Colloids and Surfaces B Biointerfaces, Journal Year: 2025, Volume and Issue: 249, P. 114492 - 114492

Published: Jan. 5, 2025

Language: Английский

---

Design and Synthesis of Isatin Derivative Payloaded Peptide-Drug Conjugate as Tubulin Inhibitor against Colorectal Cancer

European Journal of Medicinal Chemistry, Journal Year: 2025, Volume and Issue: 285, P. 117276 - 117276

Published: Jan. 12, 2025

Language: Английский

---

Circular RNAs modulate cancer drug resistance: advances and challenges

Cancer Drug Resistance, Journal Year: 2025, Volume and Issue: unknown

Published: March 28, 2025

Acquired drug resistance is a main factor contributing to cancer therapy failure and high mortality, highlighting the necessity develop novel intervention targets. Circular RNAs (circRNAs), an abundant class of RNA molecules with closed loop structure, possess characteristics including stability, which provide unique advantages in clinical application. Growing evidence indicates that aberrantly expressed circRNAs are associated against various treatments, targeted therapy, chemotherapy, radiotherapy, immunotherapy. Therefore, targeting these aberrant may offer strategy improve efficiency therapy. Herein, we present summary most recently studied their regulatory roles on resistance. With advances artificial intelligence (AI)-based bioinformatics algorithms, could emerge as promising biomarkers targets

Language: Английский

---

Comprehensive insights of etiological drivers of hepatocellular carcinoma: Fostering targeted nano delivery to anti-cancer regimes

Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, Journal Year: 2025, Volume and Issue: unknown, P. 189318 - 189318

Published: April 1, 2025

Language: Английский

---

MicroRNA-targeted nanoparticle delivery systems for cancer therapy: current status and future prospects

Nanomedicine, Journal Year: 2025, Volume and Issue: unknown, P. 1 - 14

Published: April 15, 2025

Recently, the regulatory effects of microRNAs (miRNAs) on gene expression have been exploited for applications in diagnosis and treatment cancer, neurological diseases, cardiovascular diseases. However, susceptibility miRNAs to degradation during somatic circulation challenges associated with their delivery target tissues cells limited clinical application miRNAs. For tumor therapy, it is essential specifically cancer cells. Therefore, various novel miRNA systems that protect against activity serum nuclease deliver developed optimized. This review introduces passive active targeting strategies nanoparticles, summarizes recent progress nanocarriers tumor-targeting ability, discusses nanoparticle antitumor applications. Additionally, this focuses translational potential advancing miRNA-based therapies into clinic.

Language: Английский

---

Bovine serum albumin-Camptothecin nanoparticles for RNAs packaging to improve the prognosis of Cancer

International Journal of Biological Macromolecules, Journal Year: 2024, Volume and Issue: 282, P. 136997 - 136997

Published: Oct. 30, 2024

Language: Английский

---

Lipid Nanoparticle (LNP) ‐A Vector Suitable for Evolving Therapies for Advanced Hepatocellular Carcinoma (HCC)

Global Challenges, Journal Year: 2024, Volume and Issue: 9(1)

Published: Nov. 25, 2024

Abstract Hepatocellular carcinoma (HCC) stands as the predominant form of primary liver cancer, characterized by a dismal prognosis. Therapeutic options for advanced HCC remain sparse, with efficacy significantly hampered emergence drug resistance. In parallel research into novel pharmacological agents, advances in delivery systems represent promising avenue overcoming Lipid nanoparticles (LNPs) have demonstrated considerable nucleic acid‐based therapeutics and hold potential broader applications delivery. This review describes development LNPs tailored treatment consolidates recent investigations using to target HCC.

Language: Английский

---

Drug combinations of camptothecin derivatives promote the antitumor properties

European Journal of Medicinal Chemistry, Journal Year: 2024, Volume and Issue: 279, P. 116872 - 116872

Published: Sept. 12, 2024

Language: Английский

---